 SAN DIEGO, July 08, 2020 -- Crinetics Pharmaceuticals, Inc. Nasdaq: CRNX, a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that the U.S. Food and Drug Administration FDA has granted paltusotine Orphan Drug Designation for the treatment of acromegaly. 